Cancer Biology and Immunotherapy (usg)

Event Information

Share this event

Date and Time



The DeSoto Savannah

15 East Liberty

Savannah, GA 31401

View Map

Refund Policy

Refund Policy

No Refunds

Event description
Cancer Biology and Immunotherapy

About this Event

About CBI-2020


JanusJanus was the Roman god of beginnings and transitions. It is depicted as a two-faced image that looks to the future and the past. As first pointed out by Dr. Olivera Finn, the Janus principle can be used to illustrate the past accomplishments and future opportunities in Immunotherapy of Cancer. In this case, immune function/tumor rejection and immune dysfunction/tumor progression. Ann Oncol 2012 Sep 23 (Suppl 8).

About Cancer Biology and Immunotherpay-2020

To date, the passive immunotherapeutic approaches which have been FDA-approved clearly provide clinical benefit to a proportion of advanced disease patients. While these treatments have been heralded as much needed improvements, the nearly 600,000 Americans who died of cancer last year did not gain the level of benefit we would have hoped from modern cancer care. As the frontiers of cancer immunotherapy are pushing forward, we need to concentrate on integrative translational medicine. We are proposing to have an outlet for a comprehensive discussion, which will simultaneously integrate a deep understanding of the biology of cancer along with the development of future treatment concepts to ultimately realize the full potential of this clinical revolution.

To this end, together with the United Scientific Group (USG) and under the auspices of the Mercer Medical School, Savannah Campus is organizing a Cancer Biology and Immunotherapy (CBI) meeting in Savannah, Georgia in March 30 to April 1, 2020. USG has successfully organized four Vaccine Research and Development meetings and during these events it has become apparent the cancer vaccine and immunotherapy research portions need to be expanded to their own conference.

Cancer has clearly thwarted many treatment approaches, including oncogene-driven targeted agents, monoclonal antibodies, as well as immune-modulatory agents like interferons, lymphokines, and cytokines, and various anti-angiogenic agents. With this checkered past, one has to ask the hard questions: were the concepts incorrect or were the treatments used without a full understanding of the biology of the disease? Was a complete accounting made of the host-tumor interactions? Did we fully understand the complex mechanisms inherent to the tumor microenvironment, which could render many of these treatments ineffective?

All too often pragmatic decisions, such as manufacturing requirements or financial decisions, have driven cancer R&D development and clinical trial design. Commercial strategy was crafted based on these limitations, such as ignoring early-stage or minimal residual disease patients to focus on late-stage or recurrent tumors which would achieve a clinical readout on a faster timescale. Furthermore, using cancer vaccines as a monotherapy in advanced disease patients, which flies in the face of the conventional tenets of vaccinology. Furthermore, targeting our treatments of various tumors while ignoring the magnitude and consequences of near limitless intra- and inter-tumoral genomic heterogeneity has been a major challenge. Also, in many cases, malignant progression is accompanied by major immune suppression. While successful treatments of passive immunotherapy are being heralded, the immune suppressive state of advanced disease is clinically limited. Possible combinatorial treatments of active and passive immunotherapy are warranted. These discussions will be topics of this first CBI meeting.

Meeting Topics

  • Cancer Pathology, tumor growth kinetics
  • Cancer Metastasis
  • Genomic Heterogeneity
  • Among different patients
  • Within Primary tumors
  • Among cells that metastasize
  • Within metastatic lesions
  • Passive Immunotherapy
  • Checkpoint inhibitors
  • CAR-T
  • Tumor infiltrating lymphocytes
  • Monoclonal Antibodies
  • Laboratory and Industry production
  • Immunotherapy beyond Checkpoint Inhibitors
  • Host-Tumor Interactions
  • Cancer Vaccines: Design and medical translation
  • Active Specific Immunotherapy
  • Patient selection for clinical trials: Advanced, Occult disease
  • Adjuvants, development of biocompatible delivery systems
  • Vaccine design and production technology
  • Neoproteins and neoepitopes
  • Cancer treatment monitoring and drug design
  • Cancer Prevention
  • Status Australian trials of HPV vaccine for Cervical Cancer


Plenary Session Monday March 30, 2020

8:30-9:00 Welcome and Introductions

9:00 9:30 Dr. Olivera Finn: Immuno-Oncology: Understanding the Function and

Dysfunction of the Immune System in Cancer.

9:40-10:10 Professor J J O’leary: Cancer Pathology and tumor growth kinetics,

Metastasis and tumor cell-stroma relationships.

10:20-10:50 Dr. Heyu Ni: The role of blood platelets in tumorigenesis, metastasis,

and tutor-associated thrombosis

11:00-11:30 Dr. Julie Magarian Blander: Innate Immunity in Immunotherapy,

Macrophages and Dendritic cells.

11:40-12:10 Dr. Charles Swanton: Intratumor Heterogeneity: Evolution through

Space and time.

12-20-12:50 Dr. Michael Hwang: Mutations in oncogenes and tumor suppressor

genes drive tumorigenesis: Translation for therapeutic purposes.

12:50-2:00 Lunch

2:00-2:30 Dr. Jason David Howard: Passive Immunotherapy in Advanced Disease

Cancer Patients.

2:40-5:30 Session 1. Passive Immunotherapy.

Chairmen, Dr. Jason David Howard and Dr. Robert Dillman

Plenary Session Tuesday March 31. 2020

8:00-8:30 Dr. Shruti Naik, Two to Tango: Dialogue between Immunity and Stem

Cells in Health and Disease.

8:40-9:10 Dr. Keith Knutson, Immunotherapy beyond Checkpoint Inhibitors

9:10-9:40 Dr. Robert Dillman, Cancer Vaccines: Evolution of Therapeutic


10:00-10:15 Coffee Break

10:15-10:45 Dr. Michael G. Hanna Jr., Personalized Cancer Vaccines: Design and

Clinical application

10:55-11:25 Dr. Vincent K. Tuohy. Primary Immunoprevention of Adult Onset


11:35-12:35 Lunch

12:35-3-30 Session 2. Active Specific Immunotherapy.

Chairmen, Dr. Robert Dillman and Dr Vincent Tuohy

3:30-5-30 Panel Discussion

5:30-7:00 Refreshments, View Poster presentations and Cocktails

Plenary Session Wednesday April 1, 2020

8:30-9:00 Dr. Peter Nara, Precision Oncology-where are we and where are we to go.

9:10-9:50 Dr. Martin D’sousa, Exploring nanoparticles as adjuvants in cancer


10:00 -12:00 Session 3 Cancer treatment monitoring and drug design, Chairmen,

Dr. Peter Nara and Dr. Martin D’Sousa.

12:00-1:00 LUNCH

1:00-1:30 Dr. David Hawkes, Cancer Prevention, HPV vaccine for Cervical Cancer

1:40- 3:40 Plenary Session 4, Wednesday April 1, 2020 Cancer Prevention.

Chairman, Dr. David Hawkes.

Meeting Close or Panel Discussion 3:40 to 5:30.

Possible Banquet sponsored by exhibitor.

Plenary Speakers

Michael Hwang

Vogelstein Laboratory, JHMI

Keith Knutson

Mayo Clinic

Charles Swanton

University College London

Heyu Ni

University of Toronto, CA.

Vincent K. Tuohy

Cleveland Clinic, Lerner Research. Institute.

David Hawkes

Victorian Cytology Services

John J. O’leary

Trinity College. Dublin

Julie Magarian Blander

Weill Cornell Medicine The Jill Roberts Institute for Research in Inflammatory Bowel Disease

Shruti Naik

New York University School of Medicine

"Please contact the event manager Marilyn (marilyn.b.turner@nyeventslist.com ) below for:

- Multiple participant discounts

- Price quotations or visa invitation letters

- Payment by alternate channels (PayPal, check, Western Union, wire transfers etc)

- Event sponsorships


Service fees included in this listing.


United Scientific Group - New York Events List






Share with friends

Date and Time


The DeSoto Savannah

15 East Liberty

Savannah, GA 31401

View Map

Refund Policy

No Refunds

Save This Event

Event Saved